BioMérieux: Oddo BHF still a buyer
(CercleFinance.com) - Oddo BHF confirms its Outperform recommendation on the stock, with an unchanged target price of E132, following the group's results.
The analyst says that Q4 sales came to E1,109.2m (+10.2%/+10.1% cc.), or E3,980m for FY 2024 (vs. consensus of E3,951m e), up 8.3% (+10.3% cc.).
Operating income reached E673m, +10.4% and +20% cc (consensus E648m e), i.e. an operating margin of 16.9% (vs. 16.6% in 2023).
The analyst also notes that bioMérieux is targeting 2025 sales of at least E4,260m and operating profit of E740m, i.e., up 17.4%. The consensus forecasts sales of E4,278m (median/+7.4%), with operating profit of E730m (OM: 17% e), which seems to be both in line and within reach (Oddo BHF: E4,340m/E770m).
BioMérieux targets growth of 7% p.a. and an operating margin of 20% by 2028.
This publication is positive and confirms our rating. bioMérieux gives details of its guidance, which appears rather cautious. The stakes for 2025 are: i/ the development of Spotfire (we are optimistic), ii/ the appreciation of the OM (2024 shows the effects of the GO 2028 plan), Oddo BHF explains.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The analyst says that Q4 sales came to E1,109.2m (+10.2%/+10.1% cc.), or E3,980m for FY 2024 (vs. consensus of E3,951m e), up 8.3% (+10.3% cc.).
Operating income reached E673m, +10.4% and +20% cc (consensus E648m e), i.e. an operating margin of 16.9% (vs. 16.6% in 2023).
The analyst also notes that bioMérieux is targeting 2025 sales of at least E4,260m and operating profit of E740m, i.e., up 17.4%. The consensus forecasts sales of E4,278m (median/+7.4%), with operating profit of E730m (OM: 17% e), which seems to be both in line and within reach (Oddo BHF: E4,340m/E770m).
BioMérieux targets growth of 7% p.a. and an operating margin of 20% by 2028.
This publication is positive and confirms our rating. bioMérieux gives details of its guidance, which appears rather cautious. The stakes for 2025 are: i/ the development of Spotfire (we are optimistic), ii/ the appreciation of the OM (2024 shows the effects of the GO 2028 plan), Oddo BHF explains.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.